Abstract
Objective: to evaluate the course and outcomes of ACS in patients with type 2 diabetes taking SGLT-2 inhibitors. Materials and methods: the study included patients admitted to the Research Institute – Regional Clinical Hospital No. 1 n.a. Prof. S.V. Ochapovsky” Krasnodar from 01.11.2023 to 01.02.2024. Results: a retrospective analysis of medical documentation revealed that the number of patients with ACS while taking NGLT-2 inhibitors was significantly lower compared to those taking other glucose-lowering therapy. Patients taking iNGLT-2 had a significantly lower body mass index. Significant differences concern markers of liver dysfunction and microalbuminuria, which were significantly lower in the group receiving NGLT-2. In addition, these patients were less likely to experience hospital complications such as acute kidney injury, cardiac arrhythmias, ischemic stroke, left ventricular thrombus formation, and death. Conclusions: the results of local experience with the use of iNGLT-2 in hospitalized patients with type 2 diabetes and ACS are presented, confirming the metabolic and cardiorenal benefits of this class of drugs in real clinical practice. In addition, the study results clearly demonstrate a more stable course of ACS and a lower risk of in-hospital complications and mortality. However, these parameters did not achieve statistically significant results due to the small sample.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
